Rami S. Komrokji, MD:This patient has several risk factors. He’s anemic, has leukocytosis, there is presence of circulating blasts, and he has a trisomy 8 that’s considered to be an unfavorable karyotype. Again, in the newer cytogenetic risk groups there is a very high-risk karyotype that is unfavorable. This patient fits the unfavorable cytogenetic risk group. He will come into a higher-risk group. We don’t know information about other somatic mutations, but just based on those variables he will be a patient who fits in the intermediate- to higher-risk group.
I want to emphasize, first, that we spend time making sure that we have the right diagnosis. We risk-stratify the patients, and based on that, we then develop our plan for therapy. For those patients who are higher risk, we consider an allogeneic stem cell transplant because it remains the only curative option for this disease.
In general, the cure rates are around 40% to 50%, but the procedure is associated with around a 20% transplant-related mortality and 1 to 2 years of quality of life may be affected. So we weigh the benefits and the risks. In patients who are intermediate or higher risk, I think the benefits outweigh the risks, particularly if patients are functional and don’t have major comorbidities. Unfortunately, the majority of patients may not be candidates for allogeneic stem cell transplant given the age of those patients or presence of other comorbidities. In general, probably only 10% to 20% of patients will get the transplant.
So unfortunately, most patients will not be candidates for allogeneic stem cell transplant, either given their age or presence of comorbidities. Roughly only 10% to 20% of patients will proceed to allogeneic stem cell transplant. For the rest of the patients, we tailor the treatment based on symptoms. We can divide patients into 3 groups: 1), where there is a major symptom or driver for treatment with constitutional symptoms and splenomegaly. Those usually go hand in hand. In the other group, the main indication for treatment is cytopenias, and namely anemia. And probably the most challenging group is when we have a combination of constitutional symptoms, splenomegaly, and anemia.
For patients with constitutional symptoms and splenomegaly, those typically are the ones who we think of JAK2 inhibitors for, like ruxolitinib. The treatment has been approved by the FDA for many years now. A couple of major studies that were randomized showed benefit for ruxolitinib for the treatment of patients with myelofibrosis.
There were 2 major studies: One called the COMFORT-I, which was done in the United States, and the COMFORT-II, which was carried in Europe. They were similar in design. COMFORT-I compared ruxolitinib to placebo, versus COMFORT-II, to best available therapy. One looked at the 24-week mark and the other looked at the 48-week mark, but now we have longer follow-up on those 2 studies.
The studies have shown that ruxolitinib was effective in reducing spleen and improving symptoms roughly in around 40% of the patients meeting the primary endpoint, which looked at a spleen reduction by MRI [magnetic resonance imaging] of more than 35%, which typically correlates to 50% reduction in the spleen by physical exam.
However, most patients actually derive more of a benefit than that, in terms that they all get some spleen reduction. It may not be to the point of the 50% reduction, but that still translates to a clinical benefit for the patient. And also, they get symptom improvement with the treatment.
Transcript edited for clarity.
Case: 66-Year-Old Man Diagnosed With Primary Myelofibrosis
January 2019
Savona Discusses First-Line JAK Inhibition for Patients With Myelofibrosis at Risk of Anemia
April 17th 2024During a Case-Based Roundtable® event, Michael Savona, MD, and participants discussed the case of a patient with myelofibrosis and moderate anemia receiving JAK inhibitor therapy.
Read More
PTCy Offers New Hope for Mismatched Stem Cell Transplants in Leukemia, MDS
April 13th 2024Jeff Auletta, MD, discussed how PTCy-based graft-vs-host disease prophylaxis offers a promising approach for expanding access to successful cell transplantation regardless of donor match or patient ethnicity.
Read More
Scott Evaluates Treatment Options for Hydroxyurea-Resistant Polycythemia Vera
March 28th 2024In a Community Case Forum event in partnership with the Washington State Medical Oncology Society, Bart Scott, MD, broke down various trials of hydroxyurea, ruxolitinib, and interferon in patients with polycythemia vera to assess outcomes such as hematocrit control and molecular response.
Read More
Weighing the Triggers for Initiating JAK2 Inhibition Therapy in MF
March 23rd 2024During a Case-Based Roundtable® event, Raajit K. Rampal, MD, PhD, discussed the triggers physicians need to consider when deciding to initiate therapy for patients with myelofibrosis in the first article of a 2-part series.
Read More
Participants Discuss Treating a Patient With Myelofibrosis and Anemia
March 18th 2024During a Targeted Oncology™ Case-Based Roundtable™ event, Salman Fazal, MD, discussed with participants which symptoms of myelofibrosis impact their quality of life and how they would treat a patient experiencing anemia.
Read More